2019 IPC Events
Join us at these events to expand your knowledge about psoriasis.
Wednesday, September 18, 2019 2:00 pm – 6:00 pm
Program chairs: Michel Gilliet, Switzerland; Johann Gudjonsson, USA; Jörg Prinz, Germany Program faculty: Hervé Bachelez, France; Francesca Capon, UK; Chyung-Ru Wang, USA; Poster Presentations: Renáta Bozó, Hungary; Ian Catlett, UK; Athanasios Niaouris, UK; Ashley Rider, UK; Mariusz Sikora, Poland; Enikö Pivarcsi Sonkoly, Sweden; Christian Thoma, Germany
This program is sponsored in part by Boehringer-Ingelheim.
Wednesday, October 9, 2019 9:00 am - 12:00 pm
Program chairs: Catherine Smith, UK; Bruce Strober, USA Program faculty: Lone Skov, Denmark; Robert Strohal, Austria; Tiago Torres, Portugal
This program is sponsored in part by Samsung Bioepis and Biogen.
November 8, 2019 3:30 pm – 5:30 pm
Program Chairs: Jonathan Barker, UK; Christopher Griffiths, UK Program faculty: Hervé Bachelez, France; Masamoto Murakami, Japan; Kazumitsu Sugiura, Japan
Thursday, February 28, 2019 2:00 pm – 5:00 pm
Program chair: Arnon D. Cohen, Israel Program faculty: Robert Bissonnette, Canada; Jennifer Murase, USA; Jashin Wu, USA
Thursday, April 4, 2019 1:00 pm - 5:00 pm
Friday, April 5, 2019 9:00 am - 5:00 pm
Program chairs: Mahira El Sayed, Egypt; Mohamed El-Komy, Egypt International faculty: Chris Griffiths, UK; Peter van de Kerkhof, the Netherlands
Thursday, April 25, 2019 9:30 pm – 11:30 am
Program chair: Peter van de Kerkhof, the Netherlands Program faculty: Errol Prens, the Netherlands; Marieke Seyger, the Netherlands; Fernando Valenzuela, Chile; Ron Vender, Canada
Thursday, May 2, 2019 12:00 - 5:00 pm
Friday, May 3, 2019 9:00 am - 5:00 pm
Program chairs: Claudia de la Cruz, Chile; Ricardo Romiti, Brazil International faculty: Alan Menter, USA ; Peter van de Kerkhof, the Netherlands Regional faculty: Matías Maskin, Argentina; Fernando Valenzuela, Chile
Friday, May 3, 2019 2:30 pm - 4:00 pm
Program chairs: Cristina Echeverría, Argentina & César Gonzalez, Colombia Program faculty: Paula Luna, Argentina & Enrique Rivas, Guatemala
Wednesday, May 8, 2019 9:00 am - 1:00 pm
Program chairs: April Armstrong, USA; Johann Gudjonsson, USA; Nehal Mehta, USA Program faculty: Hafid Ait-Oufella, France; Joel Gelfand, USA; Marlies Wakkee, the Netherlands
This program is supported in part by an educational grant from AbbVie.
Monday, June 10, 2019 1:30 pm – 4:30 pm
Program chair: Jonathan Barker, UK Program faculty: Hervé Bachelez, France; Lars Iversen, Denmark; Kelly Cordoro, USA; Omid Zagari, Iran
congress coverage AAD 2019 Annual Meeting Read the psoriasis highlights from the congress learn more
UPCOMING EVENT The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory? Wednesday, September 18, 2019 2:00 pm - 6:00 pm Bordeaux, france Register Now
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News